Out to pioneer gene editing in China, EdiGene bags $67M to begin clinical testing for β-thalassemia therapy, universal CAR-T
A gene editing player hailing from Beijing has clinched $67 million to steer two of its lead candidates into the clinic — and to prove itself as a CRISPR pioneer in China.
EdiGene gathered the Series B from a slate of top-tier Chinese investors, including 3H Health Investment (who led the round), Sequoia Capital China, Alwin Capital and Kunlun Capital. Previous backers, including IDG Capital, Lilly Asia Venture, Huagai Capital and Green Pine Capital Partners, also participated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.